AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody

Published: 2025-07-10 08:51:00 ET ABBV

Published on 07/10/2025 at 08:51

AbbVie and IGI Therapeutics SA announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT®? protein platform, for oncology and autoimmune diseases. Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan and Greater China.